Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | PTPRB | P23467 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123113 | 0.85 | CA12 (0.35) | CA12CA1CA2CA14CA7 | |
| SCHEMBL12974880 | 0.83 | KDM4E (0.39) | CA12CA1CA2CA14CA7 | |
| SCHEMBL28568915 | 0.83 | CA12 (0.37) | CA12CA1CA2CA14CA7 | |
| SCHEMBL18341107 | 0.81 | CA12 (0.36) | CA12CA1CA2CA14CA7 | |
| SCHEMBL14280306 | 0.79 | TDP1 (0.37) | CA12CA1CA2CA14CA7 | |
| SCHEMBL4756714 | 0.78 | CA1 (0.41) | CA12CA1CA2CA14CA7 | |
| SCHEMBL5146359 | 0.78 | CA12 (0.37) | CA12CA1CA2CA14CA7 | |
| SCHEMBL7923566 | 0.77 | CA2 (0.42) | CA12CA1CA2CA14CA7 | |
| SCHEMBL1964837 | 0.76 | TDP1 (0.40) | CA12CA1CA2CA14CA7 | |
| SCHEMBL21187934 | 0.76 | TDP1 (0.38) | CA12CA1CA2CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| CN-108295073-B | Polyfluoro compounds as bruton's tyrosine kinase inhibitors | 浙江导明医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| CN-108295073-A | Multi-fluorinated compounds are as bruton's tyrosine kinase inhibitor | 浙江导明医药科技有限公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-106061976-B | Polyfluoro compounds as bruton's tyrosine kinase inhibitors | 浙江导明医药科技有限公司 | 2018-05-15 | — | — | CN | disclosed |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138842-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| CN-106061976-A | Polyfluoro compounds as bruton's tyrosine kinase inhibitors | 浙江导明医药科技有限公司 | 2016-10-26 | — | — | CN | disclosed |
| US-20160200730-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2016-07-14 | — | — | US | disclosed |
| WO-2015165279-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | 浙江导明医药科技有限公司 | 2015-11-05 | — | — | WO | disclosed |
| CN-105017256-A | Polyfluorinated compound Bruton tyrosine kinase inhibitor | ZHEJIANG DAOMING PHARMACEUTICAL CO LTD | 2015-11-04 | — | — | CN | disclosed |
| WO-2015092819-A2 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5- AMINE | NEKTAR THERAPEUTICS (INDIA) PVT. LTD. (IN) | 2015-06-25 | — | — | WO | disclosed |
| US-7846971-B2 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| US-4698231-A | Sweetening with L-aminodicarboxylic acid amides | GENERAL FOOD CORPORATION (US) | 1987-10-06 | — | — | US | disclosed |
| US-4622418-A | LOW CALORIE SWEETENERS | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200730-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | CA12 4795/4885CA1 4806/4885CA2 3455/4885 |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | CA12 3476/4885CA1 2364/4885CA2 200/4885 |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | CA12 4795/4885CA1 4806/4885CA2 3455/4885 |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | CA12 3476/4885CA1 2364/4885CA2 200/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | CA12 3919/4885CA1 2419/4885CA2 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.